Genmab initiates phase III trial with drug against cervical cancer
Positive phase II results prompt Genmab and its collaborative partner Seattle Genetics to submit a US registration application for accelerated approval, which is given to drugs that accommodate an unmet need for the treatment of serious illnesses.
BY RITZAU FINANS, TRANSLATED BY NIELSINE NIELSEN
The biotech firm Genmab will be initiating a phase III trial program with Tisotumab Vedotin for the treatment of cervical cancer with the aim of assessing its efficiency compared with chemotherapy for patients with recurrent or metastatic cervical cancer, according to a Genmab statement on Monday evening.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
.jpg)
Novo Nordisk completes acquisition of Emisphere Technologies
For subscribers
.jpg&w=384&q=75)
